Cavinton, Ampoules 10mg, 2ml, 10pcs

Composition

1 ml of infusion solution concentrate contains:

Vinpocetine 5 mg.

Auxiliary substances:

ascorbic acid,

sodium disulfite,

tartaric acid,

benzyl alcohol,

sorbitol,

d/i water.

Pharmacological action

Cavinton is a drug that improves cerebral circulation, brain metabolism and rheological properties of blood.

It has a cerebroprotective effect. Reduces the severity of damaging cytotoxic reactions caused by stimulating amino acids; inhibits the functional activity of both cellular transmembrane sodium and calcium channels, and NMDA and AMPA receptors. Potentiates the neuroprotective effect of adenosine.

It stimulates brain metabolism, increases the absorption and assimilation of glucose and oxygen by the brain. It stimulates glucose transport through the BBB, shifts glucose metabolism to an energetically more favorable aerobic direction. Selectively inhibits Ca2+ – calmodulin-dependent cGMP phosphodiesterase, increases the concentration of cAMP and cGMP in brain tissues, as well as the concentration of ATP and the ratio of ATP/AMP. It stimulates the cerebral metabolism of norepinephrine and serotonin, stimulates the ascending noradrenergic system, and has an antioxidant effect.

The drug selectively enhances cerebral blood flow: increases the brain fraction of the minute volume; reduces the resistance of brain vessels, without affecting the parameters of general blood circulation (blood pressure, minute volume, heart rate, OPSS).

It does not cause the phenomenon of “robbing”; on the contrary, when it is used, first of all, the blood supply to the ischemic, but still viable area with low perfusion increases – the phenomenon of “reverse robbing”.

Improves the tolerance of hypoxia by brain cells, promoting the transport of oxygen to tissues due to a decrease in the affinity of red blood cells for it. The drug improves the microcirculation of the brain, inhibits platelet aggregation, reduces pathologically increased blood viscosity, increases the deformability of red blood cells and blocks their absorption of adenosine.

Pharmacokinetics

The therapeutic plasma concentration is 10-20 ng / ml. With parenteral use of Vd-5.3 l / kg — T_1/2 — 4,74–5 H. Easily penetrates through histohematic barriers (including the BBB). It is excreted by the kidneys and through the gastrointestinal tract in a ratio of 3: 2.

Indications

In neurology

• – acute and chronic cerebrovascular insufficiency (transient ischemia, progressing stroke,
• post-stroke,
• vascular dementia,
• atherosclerosis of brain vessels,
• post-traumatic and hypertensive encephalopathy,
• the vertebral-basilar insufficiency);
• mental and neurological disorders in patients with cerebrovascular insufficiency (including memory impairment, dizziness, headache, aphasia, apraxia, motor disorders).

In ophthalmology: vascular diseases of the eyes (atherosclerosis, angiospasm of the choroid and retina, degenerative diseases of the choroid, retina or macula, arterial and venous thrombosis or embolism, secondary glaucoma).

In ENT practice

• , hearing loss (vascular, toxic or age-related),
• Meniere’s disease,
• cochleovestibular neuritis,
• tinnitus,
• dizziness (labyrinth origin);
• vasovegetative manifestations of menopausal syndrome.

Use during pregnancy and lactation

Contraindicated in pregnancy. Vinpocetine penetrates the placental barrier.

At the same time, its concentration in the placenta and fetal blood is lower than in the blood of a pregnant woman.

At high doses, placental bleeding and spontaneous abortions are possible, probably as a result of increased placental blood supply.

Within an hour,0.25% of the taken dose of the drug penetrates into breast milk.

When using the drug, it is necessary to stop breastfeeding.

Contraindications

• known hypersensitivity to vinpocetine;
• acute phase of hemorrhagic stroke;
• severe coronary heart disease;
• severe arrhythmia;
• pregnancy;
• lactation;
• children under 18 years of age ( due to insufficient data).

Side effects

From the cardiovascular system: it is possible to increase the manifestations of existing arrhythmia.

From the digestive system: nausea, heartburn, dry mouth.

From the central nervous system: headache, dizziness, sleep disturbance, weakness.

Allergic reactions: skin rash, urticaria.

Skin reactions: hyperemia of the skin.

Interaction

Not observed when used concomitantly with pindolol, clopamide, glibenclamide, digoxin, acenocoumarol and hydrochlorothiazide; imipramine.

In rare cases, concomitant use with alpha-methyldopa is accompanied by a slight increase in the antihypertensive effect, with the use of such a combination, regular blood pressure monitoring is necessary.

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when prescribing concomitantly with drugs of central, antiarrhythmic and anticoagulant action.

Cavinton concentrate for the preparation of an infusion solution and heparin are chemically incompatible, so it is forbidden to introduce them in the same infusion mixture, but you can simultaneously treat with anticoagulants and vinpocetine.

Cavinton concentrate for infusion solution preparation is incompatible with infusion solutions containing amino acids, so they cannot be used to dilute the drug.

How to take, course of use and dosage

Intravenous, drip, slow (maximum infusion rate-80 drops / min).

It is forbidden to enter intramuscularly and without dilution intravenously.

To prepare the infusion, you can use saline or dextrose-containing solutions (Ringer, Salsol, Rindex, Reomacrodex).

The usual initial daily dose is 20 mg (2 amp. ) in 500 ml of infusion solution. Depending on the tolerance, the dose can be increased to no more than 1 mg/kg/day for 2-3 days. The average duration of treatment is 10-14 days.

The average daily dose for a body weight of 70 kg is 50 mg (5 ampoules in 500 ml of infusion solution).

No dose adjustment is required for liver and kidney diseases.

At the end of the course of intravenous therapy, it is recommended to continue treatment with Cavinton forte tablets (1 tablet 3 times a day) or Cavinton (2 tablets 3 times a day).

Infusion solution with Cavinton should be used in the first 3 hours after preparation.

Overdose

Currently, data on vinpocetine overdose are limited.

Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.

Special instructions

Cavinton infusion solution concentrate contains sorbitol (160 mg / 2 ml), so if you have diabetes, you should periodically monitor your blood sugar level.

In case of fructose intolerance or fructose 1,6-diphosphatase deficiency, the use of vinpocetine as an infusion solution concentrate should be avoided.

Effect of the drug on the ability to drive a car. There are no data on the effect of vinpocetine on the ability to drive a car and work mechanisms.

Form of production

Concentrate for preparation of solution for infusions

Storage conditions

In a dark place, at a temperature of 15-30 °C

Shelf life

5 years

Active ingredient

Vinpocetine

Conditions of release from pharmacies

By prescription

Dosage form

infusion solution